References
- Struyk L, Hawes GE, Dolhain RJ, van Scherpenzeel A, Godthelp B, Breedveld FC, et al. Evidence for selective in vivo expansion of synovial tissue-infiltrating CD4+CD45RO-FT lymphocyte on the basis of CDR3 diversity. Int Immunol. 1994;6: 897–907.
- Fugger L, Svejgaard A. Association of MHC and rheumatoid arthritis. HLA-DR4 and rheumatoid arthritis: studies in mice and human. Arthritis Res Ther. 2000;2: 208–11.
- Londei M, Savill CM, Verhoef A, Brennan F, Leech ZA, Duance V, et al. Persistence of collagen type II-specific T cell clones in the synovial membrane of a patient with rheumatoid arthritis. Proc Natl Acad Sci USA. 1989;86:636–40.
- Saeki T, Kato T, Masuko-Hongo K, Nakamura H, Yoshino S, Nishioka K, et al. Type II collagen is a target antigen of clonally expanded T cells in the synovium of patients with rheumatoid arthritis. Ann Rheum Dis. 1999;58:446–50.
- Luross JA, Williams NA. The genetic and immunopathological processes underlying collagen-induced arthritis. Immunology. 2001;103:407–16.
- Magistris MTD, Alexander J, Coggeshall M, Altman A, Gaeta FC, Grey HM, et al. Antigen analog-major histocompatibility complexes act as antagonists of the T cell receptor. Cell. 1992;68:625–34.
- Pfeiffer C, Stein J, Aouthwood S, Ketelaar H, Sette A, Bottomly K. Altered peptide ligands can control CD4 T lymphocyte dif-ferentiation in vivo. J Exp Med. 1995;181:1569–74.
- Ohnishi Y, Tsutsumi A, Matsumoto I, Goto D, Ito S, Kuwana M, et al. Altered peptide ligands control type II collagen-reactive T cells from rheumatoid arthritis patients. Mod Rheumatol. 2006;16:226–8.
- Wraith DC, Smilek DE, Mitchell DJ, Steinman L, McDevitt HO. Antigen recognition in autoimmune encephalomyelitis and the potential for peptide-mediated immunotherapy. Cell. 1989;59:247–55.
- Myers LK, Rosloniec EF, Seyer JM, Stuart JM, Kang AH. A synthetic peptide analogue of a determinant of type II collagen prevents the onset of collagen-induced arthritis. J Immunol. 1993;150:4652–8.
- Miller SD, Turley DM, Podojil JR. Antigen-specific tolerance strategies for the prevention and treatment of autoimmune dis-ease. Nat Rev Immunol. 2007;7:665–77.
- Nakae S, Nambu A, Sudo K, Iwakura Y. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol. 2003;171:6173–7.
- Myers LK, Tang B, Rosloniec EF, Stuart JM, Chiang TM, Kang AH. Characterization of a peptide analogue of a determinant of type II collagen that suppress collagen-induced arthritis. J Immunol. 1998;161:3589–95.
- Zhao J, Li R, He J, Shi J, Long L, Li Z. Mucosal administration of an altered CI1263-272 peptide inhibits collagen-induced arthritis by suppression of 'Thl/Th17 cells and expansion of regulatory T cells. Rheumatol Int. 2008;29:9–16.
- Vermeire K, Heremans H, Vandeputte M, Huang S, Billiau A, Matthys P. Accelerated collagen-induced arthritis in IFN-gamma receptor-deficient mice. J Immunol. 1997;158:5507–13.
- Coppieters K, Van Beneden K, Jacques P, Dewint P, Vervloet A, Vander Cruyssen B, et al. A single early activation of invariant NK T cells confers long-term protection against collagen-induced arthritis in ligand-specific manner. J Immunol. 2007;179:2300–9.